表紙
市場調査レポート

クラミジア感染症:パイプライン分析

Chlamydia Infections - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 200439
出版日 ページ情報 英文 76 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
クラミジア感染症:パイプライン分析 Chlamydia Infections - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 76 Pages
概要

クラミジア感染症は、細菌によって引き起こされる性感染症です。症状は排尿時にヒリヒリした感覚、陰茎や膣から膿のような分泌物が出る、下腹部の痛み、月経中間期の出血および痛み、睾丸周辺の腫れなどが見られます。素因としては年齢、不特定多数の性交渉相手、性感染症の前歴などが挙げられます。治療には抗生物質や鎮痛剤を用います。

当レポートでは、クラミジア感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどを提供してお届けいたします。

目次

イントロダクション

クラミジア感染症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Abera Bioscience AB
  • Adamis Pharmaceuticals Corporation
  • Big DNA Ltd.
  • CEL-SCI Corporation
  • Folia Biotech Inc.
  • Genocea Biosciences, Inc.
  • Merck & Co., Inc.
  • Osel Inc.
  • Prokarium Limited
  • QureTech Bio AB
  • Selecta Biosciences, Inc.
  • SIGA Technologies, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • Ab-03
  • acALY-18
  • BDNA-003
  • 感染症向け生物製剤
  • C-31G
  • CEL-1000
  • クラミジア・トラコマチス・ワクチン
  • クラミジア・ワクチン
  • クラミジア感染症向け病原性遮断薬
  • GEN-001
  • 阻害ペプチド CPAF クラミジア感染症向け
  • クラミジア感染症向け小分子
  • solithromycin
  • ST-669
  • VNI-201

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7860IDB

Summary

Global Markets Direct's, 'Chlamydia Infections - Pipeline Review, H1 2016', provides an overview of the Chlamydia Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chlamydia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections
  • The report reviews pipeline therapeutics for Chlamydia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chlamydia Infections therapeutics and enlists all their major and minor projects
  • The report assesses Chlamydia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chlamydia Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chlamydia Infections Overview
  • Therapeutics Development
    • Pipeline Products for Chlamydia Infections - Overview
    • Pipeline Products for Chlamydia Infections - Comparative Analysis
  • Chlamydia Infections - Therapeutics under Development by Companies
  • Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes
  • Chlamydia Infections - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Chlamydia Infections - Products under Development by Companies
  • Chlamydia Infections - Products under Investigation by Universities/Institutes
  • Chlamydia Infections - Companies Involved in Therapeutics Development
    • Abera Bioscience AB
    • Adamis Pharmaceuticals Corporation
    • CEL-SCI Corporation
    • Genocea Biosciences, Inc.
    • Merck & Co., Inc.
    • NanoBio Corporation
    • Prokarium Limited
    • QureTech Bio AB
    • Selecta Biosciences, Inc.
    • SIGA Technologies, Inc.
  • Chlamydia Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Ab-03 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • acALY-18 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-31G - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chlamydia trachomatis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chlamydia trachomatis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GEN-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Chlamydophila Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ST-669 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chlamydia Infections - Recent Pipeline Updates
  • Chlamydia Infections - Dormant Projects
  • Chlamydia Infections - Product Development Milestones
    • Featured News & Press Releases
      • Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
      • Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology
      • Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia
      • Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
      • Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
      • Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center
      • Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chlamydia Infections, H1 2016
  • Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2016
  • Chlamydia Infections - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Chlamydia Infections - Pipeline by CEL-SCI Corporation, H1 2016
  • Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H1 2016
  • Chlamydia Infections - Pipeline by Merck & Co., Inc., H1 2016
  • Chlamydia Infections - Pipeline by NanoBio Corporation, H1 2016
  • Chlamydia Infections - Pipeline by Prokarium Limited, H1 2016
  • Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2016
  • Chlamydia Infections - Pipeline by Selecta Biosciences, Inc., H1 2016
  • Chlamydia Infections - Pipeline by SIGA Technologies, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Chlamydia Infections Therapeutics - Recent Pipeline Updates, H1 2016
  • Chlamydia Infections - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Chlamydia Infections, H1 2016
  • Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top